{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Head+and+Neck+Squamous+Cell+Cancer&page=2", "query": { "condition": "Metastatic Head and Neck Squamous Cell Cancer", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Head+and+Neck+Squamous+Cell+Cancer&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-11T12:27:58.593Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00003809", "title": "Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "cisplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": null, "start_date": "1999-08-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-06-11T12:27:58.593Z", "location_count": 73, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 54 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003809" }, { "nct_id": "NCT05338905", "title": "Intensive Symptom Surveillance Guided by Machine Learning-Directed Risk Stratification in Patients With Non-Metastatic Head and Neck Cancer, The INSIGHT Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "Palliative Therapy", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2022-10-11", "completion_date": "2027-12-17", "has_results": false, "last_update_posted_date": "2026-01-23", "last_synced_at": "2026-06-11T12:27:58.593Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05338905" }, { "nct_id": "NCT04428333", "title": "Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neoplasms, Head and Neck" ], "interventions": [ { "name": "Feladilimab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Platinum based chemotherapy", "type": "DRUG" }, { "name": "Fluorouracil (5FU)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 117, "start_date": "2020-08-12", "completion_date": "2023-09-19", "has_results": true, "last_update_posted_date": "2024-10-09", "last_synced_at": "2026-06-11T12:27:58.593Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04428333" }, { "nct_id": "NCT03245489", "title": "Anti-platelet + Pembro for H&N Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Clopidogrel", "type": "DRUG" }, { "name": "acetylsalicylic acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical University of South Carolina", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2018-03-06", "completion_date": "2024-11-20", "has_results": false, "last_update_posted_date": "2025-01-31", "last_synced_at": "2026-06-11T12:27:58.593Z", "location_count": 1, "location_summary": "Charleston, South Carolina", "locations": [ { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03245489" }, { "nct_id": "NCT06064877", "title": "A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Head-and-neck Squamous-cell Carcinoma", "Recurrent Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "Ficlatuzumab", "type": "BIOLOGICAL" }, { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "AVEO Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 410, "start_date": "2024-01-11", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-04-09", "last_synced_at": "2026-06-11T12:27:58.593Z", "location_count": 28, "location_summary": "Gilbert, Arizona • Tucson, Arizona • Los Angeles, California + 23 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06064877" }, { "nct_id": "NCT05423197", "title": "89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCC", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head-and-neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "89Zr-panitumumab IV", "type": "DRUG" }, { "name": "Panitumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 60, "start_date": "2026-06", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2025-07-16", "last_synced_at": "2026-06-11T12:27:58.593Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05423197" }, { "nct_id": "NCT03625323", "title": "Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "NSCLC", "HNSCC" ], "interventions": [ { "name": "eftilagimod alpha", "type": "DRUG" }, { "name": "pembrolizumab (KEYTRUDA®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Immutep S.A.S.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 187, "start_date": "2019-02-21", "completion_date": "2024-11-25", "has_results": true, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-06-11T12:27:58.593Z", "location_count": 1, "location_summary": "Huston, Texas", "locations": [ { "city": "Huston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03625323" }, { "nct_id": "NCT05061940", "title": "This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Head and Neck Cancer", "Melanoma", "HPV-Related Malignancy", "HPV-Related Carcinoma", "HPV-Related Cervical Carcinoma", "HPV Positive Oropharyngeal Squamous Cell Carcinoma", "Lung Cancer, Nonsmall Cell", "Melanoma (Skin)" ], "interventions": [ { "name": "Tumor Profiling", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Repertoire Immune Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2021-05-05", "completion_date": "2022-10-11", "has_results": false, "last_update_posted_date": "2022-12-06", "last_synced_at": "2026-06-11T12:27:58.593Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Ann Arbor, Michigan • Nashville, Tennessee", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05061940" }, { "nct_id": "NCT06330064", "title": "A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent or Metastatic Solid Tumors" ], "interventions": [ { "name": "Ifinatamab deruxtecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 520, "start_date": "2024-04-10", "completion_date": "2028-07-25", "has_results": false, "last_update_posted_date": "2026-02-12", "last_synced_at": "2026-06-11T12:27:58.593Z", "location_count": 17, "location_summary": "Los Angeles, California • Whittier, California • Skokie, Illinois + 12 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Skokie", "state": "Illinois" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06330064" }, { "nct_id": "NCT04221893", "title": "Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Stage IV Esophageal Adenocarcinoma", "Stage IV Esophageal Squamous Cell Carcinoma", "Stage IV Gastric Cancer", "Stage IV Adenocarcinoma of the Gastroesophageal Junction", "Stage IVA Esophageal Adenocarcinoma", "Stage IVA Esophageal Squamous Cell Carcinoma", "Stage IVA Gastric Cancer", "Stage IVA Adenocarcinoma of the Gastroesophageal Junction", "Stage IVB Esophageal Adenocarcinoma", "Stage IVB Esophageal Squamous Cell Carcinoma", "Stage IVB Gastric Cancer", "Stage IVB Gastroesophageal Junction Adenocarcinoma", "Metastatic Anal Canal Carcinoma", "Metastatic Colorectal Carcinoma", "Metastatic Esophageal Carcinoma", "Metastatic Gastric Carcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Metastatic Hepatocellular Carcinoma", "Metastatic Malignant Digestive System Neoplasm", "Metastatic Small Intestinal Carcinoma", "Pancreatobiliary Carcinoma", "Pathologic Stage IV Gastric Cancer AJCC v8", "Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8", "Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8", "Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC V8", "Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Stage IV Anal Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IV Hepatocellular Carcinoma AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVA Hepatocellular Carcinoma AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Stage IVB Hepatocellular Carcinoma AJCC v8", "Stage IVC Colorectal Cancer AJCC v8" ], "interventions": [ { "name": "Radiation Therapy (RT)", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2020-08-07", "completion_date": "2028-04-30", "has_results": false, "last_update_posted_date": "2025-10-06", "last_synced_at": "2026-06-11T12:27:58.593Z", "location_count": 2, "location_summary": "San Francisco, California • Walnut Creek, California", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Walnut Creek", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04221893" } ] }